ABO blood group barrier in allogeneic bone marrow transplantation revisited

Jörg D. Seebach, Georg Stussi, Jakob R. Passweg, Fausto R. Loberiza, James L. Gajewski, Armand Keating, Martin Goerner, Philip A. Rowlings, Pierre Tiberghien, Gerald J. Elfenbein, Robert Peter Gale, Jon J. van Rood, Vijay Reddy, Eliane Gluckman, Brian J. Bolwell, Thomas R. Klumpp, Mary M. Horowitz, Olle Ringdén, A. John Barrett

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Reports have shown a worse outcome for donor-recipient pairs mismatched for ABO blood groups in bone marrow transplantation (BMT). These studies, however, included small and heterogenous study populations, and not all considered bidirectional ABO incompatibility separately. Because the issue remains controversial, we analyzed the effect of ABO mismatch on the overall survival, transplant-related mortality, and occurrence of acute and chronic graft-versus-host disease (GVHD) in a large homogenous group of patients undergoing allogeneic BMT. A total of 3103 patients with early-stage leukemia who underwent transplantation between 1990 and 1998 with bone marrow from an HLA-identical sibling and who were reported to the Center for International Blood and Marrow Transplant Research were studied. The median follow-up was 54 months. A total of 2108 (67.9%) donor-recipient pairs were ABO identical, 451 (14.5%) had a minor mismatch, 430 (13.9%) had a major mismatch, and 114 (3.7%) had a bidirectional ABO mismatch. The groups did not differ significantly in patient or donor characteristics except for more female-to-male sex mismatch in the bidirectional ABO mismatch group (P = .017). In multivariate models of overall survival, transplant-related mortality, and grade II to IV acute GVHD, there were no significant differences among the 4 groups. Bidirectional ABO mismatch was associated with a significantly higher risk of grade III or IV acute GVHD (hazard ratio, 1.869; 95% confidence interval, 1.192-2.93; P = .006). Patients with major ABO mismatch received red blood cell transfusions (P = .001) for a longer timer after transplantation and had a slightly slower neutrophil recovery (P <.001). There was no evidence of a substantial effect of ABO blood group incompatibility on the outcome of conventional BMT among patients with leukemia.

Original languageEnglish (US)
Pages (from-to)1006-1013
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume11
Issue number12
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Homologous Transplantation
Blood Group Antigens
Bone Marrow Transplantation
Graft vs Host Disease
Tissue Donors
Transplants
Leukemia
Transplantation
Bone Marrow
Blood Group Incompatibility
Erythrocyte Transfusion
Survival
Mortality
Siblings
Neutrophils
Confidence Intervals
Research
Population

Keywords

  • ABO blood groups
  • Bone marrow transplantation
  • Engraftment
  • GVHD
  • Survival

ASJC Scopus subject areas

  • Transplantation

Cite this

Seebach, J. D., Stussi, G., Passweg, J. R., Loberiza, F. R., Gajewski, J. L., Keating, A., ... Barrett, A. J. (2005). ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biology of Blood and Marrow Transplantation, 11(12), 1006-1013. https://doi.org/10.1016/j.bbmt.2005.07.015

ABO blood group barrier in allogeneic bone marrow transplantation revisited. / Seebach, Jörg D.; Stussi, Georg; Passweg, Jakob R.; Loberiza, Fausto R.; Gajewski, James L.; Keating, Armand; Goerner, Martin; Rowlings, Philip A.; Tiberghien, Pierre; Elfenbein, Gerald J.; Gale, Robert Peter; van Rood, Jon J.; Reddy, Vijay; Gluckman, Eliane; Bolwell, Brian J.; Klumpp, Thomas R.; Horowitz, Mary M.; Ringdén, Olle; Barrett, A. John.

In: Biology of Blood and Marrow Transplantation, Vol. 11, No. 12, 12.2005, p. 1006-1013.

Research output: Contribution to journalArticle

Seebach, JD, Stussi, G, Passweg, JR, Loberiza, FR, Gajewski, JL, Keating, A, Goerner, M, Rowlings, PA, Tiberghien, P, Elfenbein, GJ, Gale, RP, van Rood, JJ, Reddy, V, Gluckman, E, Bolwell, BJ, Klumpp, TR, Horowitz, MM, Ringdén, O & Barrett, AJ 2005, 'ABO blood group barrier in allogeneic bone marrow transplantation revisited', Biology of Blood and Marrow Transplantation, vol. 11, no. 12, pp. 1006-1013. https://doi.org/10.1016/j.bbmt.2005.07.015
Seebach JD, Stussi G, Passweg JR, Loberiza FR, Gajewski JL, Keating A et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biology of Blood and Marrow Transplantation. 2005 Dec;11(12):1006-1013. https://doi.org/10.1016/j.bbmt.2005.07.015
Seebach, Jörg D. ; Stussi, Georg ; Passweg, Jakob R. ; Loberiza, Fausto R. ; Gajewski, James L. ; Keating, Armand ; Goerner, Martin ; Rowlings, Philip A. ; Tiberghien, Pierre ; Elfenbein, Gerald J. ; Gale, Robert Peter ; van Rood, Jon J. ; Reddy, Vijay ; Gluckman, Eliane ; Bolwell, Brian J. ; Klumpp, Thomas R. ; Horowitz, Mary M. ; Ringdén, Olle ; Barrett, A. John. / ABO blood group barrier in allogeneic bone marrow transplantation revisited. In: Biology of Blood and Marrow Transplantation. 2005 ; Vol. 11, No. 12. pp. 1006-1013.
@article{11706820f4f24c04b6e87c6803f4d1ab,
title = "ABO blood group barrier in allogeneic bone marrow transplantation revisited",
abstract = "Reports have shown a worse outcome for donor-recipient pairs mismatched for ABO blood groups in bone marrow transplantation (BMT). These studies, however, included small and heterogenous study populations, and not all considered bidirectional ABO incompatibility separately. Because the issue remains controversial, we analyzed the effect of ABO mismatch on the overall survival, transplant-related mortality, and occurrence of acute and chronic graft-versus-host disease (GVHD) in a large homogenous group of patients undergoing allogeneic BMT. A total of 3103 patients with early-stage leukemia who underwent transplantation between 1990 and 1998 with bone marrow from an HLA-identical sibling and who were reported to the Center for International Blood and Marrow Transplant Research were studied. The median follow-up was 54 months. A total of 2108 (67.9{\%}) donor-recipient pairs were ABO identical, 451 (14.5{\%}) had a minor mismatch, 430 (13.9{\%}) had a major mismatch, and 114 (3.7{\%}) had a bidirectional ABO mismatch. The groups did not differ significantly in patient or donor characteristics except for more female-to-male sex mismatch in the bidirectional ABO mismatch group (P = .017). In multivariate models of overall survival, transplant-related mortality, and grade II to IV acute GVHD, there were no significant differences among the 4 groups. Bidirectional ABO mismatch was associated with a significantly higher risk of grade III or IV acute GVHD (hazard ratio, 1.869; 95{\%} confidence interval, 1.192-2.93; P = .006). Patients with major ABO mismatch received red blood cell transfusions (P = .001) for a longer timer after transplantation and had a slightly slower neutrophil recovery (P <.001). There was no evidence of a substantial effect of ABO blood group incompatibility on the outcome of conventional BMT among patients with leukemia.",
keywords = "ABO blood groups, Bone marrow transplantation, Engraftment, GVHD, Survival",
author = "Seebach, {J{\"o}rg D.} and Georg Stussi and Passweg, {Jakob R.} and Loberiza, {Fausto R.} and Gajewski, {James L.} and Armand Keating and Martin Goerner and Rowlings, {Philip A.} and Pierre Tiberghien and Elfenbein, {Gerald J.} and Gale, {Robert Peter} and {van Rood}, {Jon J.} and Vijay Reddy and Eliane Gluckman and Bolwell, {Brian J.} and Klumpp, {Thomas R.} and Horowitz, {Mary M.} and Olle Ringd{\'e}n and Barrett, {A. John}",
year = "2005",
month = "12",
doi = "10.1016/j.bbmt.2005.07.015",
language = "English (US)",
volume = "11",
pages = "1006--1013",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - ABO blood group barrier in allogeneic bone marrow transplantation revisited

AU - Seebach, Jörg D.

AU - Stussi, Georg

AU - Passweg, Jakob R.

AU - Loberiza, Fausto R.

AU - Gajewski, James L.

AU - Keating, Armand

AU - Goerner, Martin

AU - Rowlings, Philip A.

AU - Tiberghien, Pierre

AU - Elfenbein, Gerald J.

AU - Gale, Robert Peter

AU - van Rood, Jon J.

AU - Reddy, Vijay

AU - Gluckman, Eliane

AU - Bolwell, Brian J.

AU - Klumpp, Thomas R.

AU - Horowitz, Mary M.

AU - Ringdén, Olle

AU - Barrett, A. John

PY - 2005/12

Y1 - 2005/12

N2 - Reports have shown a worse outcome for donor-recipient pairs mismatched for ABO blood groups in bone marrow transplantation (BMT). These studies, however, included small and heterogenous study populations, and not all considered bidirectional ABO incompatibility separately. Because the issue remains controversial, we analyzed the effect of ABO mismatch on the overall survival, transplant-related mortality, and occurrence of acute and chronic graft-versus-host disease (GVHD) in a large homogenous group of patients undergoing allogeneic BMT. A total of 3103 patients with early-stage leukemia who underwent transplantation between 1990 and 1998 with bone marrow from an HLA-identical sibling and who were reported to the Center for International Blood and Marrow Transplant Research were studied. The median follow-up was 54 months. A total of 2108 (67.9%) donor-recipient pairs were ABO identical, 451 (14.5%) had a minor mismatch, 430 (13.9%) had a major mismatch, and 114 (3.7%) had a bidirectional ABO mismatch. The groups did not differ significantly in patient or donor characteristics except for more female-to-male sex mismatch in the bidirectional ABO mismatch group (P = .017). In multivariate models of overall survival, transplant-related mortality, and grade II to IV acute GVHD, there were no significant differences among the 4 groups. Bidirectional ABO mismatch was associated with a significantly higher risk of grade III or IV acute GVHD (hazard ratio, 1.869; 95% confidence interval, 1.192-2.93; P = .006). Patients with major ABO mismatch received red blood cell transfusions (P = .001) for a longer timer after transplantation and had a slightly slower neutrophil recovery (P <.001). There was no evidence of a substantial effect of ABO blood group incompatibility on the outcome of conventional BMT among patients with leukemia.

AB - Reports have shown a worse outcome for donor-recipient pairs mismatched for ABO blood groups in bone marrow transplantation (BMT). These studies, however, included small and heterogenous study populations, and not all considered bidirectional ABO incompatibility separately. Because the issue remains controversial, we analyzed the effect of ABO mismatch on the overall survival, transplant-related mortality, and occurrence of acute and chronic graft-versus-host disease (GVHD) in a large homogenous group of patients undergoing allogeneic BMT. A total of 3103 patients with early-stage leukemia who underwent transplantation between 1990 and 1998 with bone marrow from an HLA-identical sibling and who were reported to the Center for International Blood and Marrow Transplant Research were studied. The median follow-up was 54 months. A total of 2108 (67.9%) donor-recipient pairs were ABO identical, 451 (14.5%) had a minor mismatch, 430 (13.9%) had a major mismatch, and 114 (3.7%) had a bidirectional ABO mismatch. The groups did not differ significantly in patient or donor characteristics except for more female-to-male sex mismatch in the bidirectional ABO mismatch group (P = .017). In multivariate models of overall survival, transplant-related mortality, and grade II to IV acute GVHD, there were no significant differences among the 4 groups. Bidirectional ABO mismatch was associated with a significantly higher risk of grade III or IV acute GVHD (hazard ratio, 1.869; 95% confidence interval, 1.192-2.93; P = .006). Patients with major ABO mismatch received red blood cell transfusions (P = .001) for a longer timer after transplantation and had a slightly slower neutrophil recovery (P <.001). There was no evidence of a substantial effect of ABO blood group incompatibility on the outcome of conventional BMT among patients with leukemia.

KW - ABO blood groups

KW - Bone marrow transplantation

KW - Engraftment

KW - GVHD

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=28744440859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28744440859&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2005.07.015

DO - 10.1016/j.bbmt.2005.07.015

M3 - Article

C2 - 16338623

AN - SCOPUS:28744440859

VL - 11

SP - 1006

EP - 1013

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -